University of Siena

ADEA Announces 2023-24 Fellows of Its Inaugural Council of Deans Fellowship

Retrieved on: 
Wednesday, June 21, 2023
Health, Other Education, University, Dental, Education, Archives of Oral Biology, Experimental pathology, DRS, CWRU, Maryland School, Chemistry, Fellows, Research, Postgraduate education, CODA, Al-Ghad International Health Sciences Colleges, Prosthodontics, Exhibition, M.A, Indiana University School of Dentistry, Harvard School of Dental Medicine, Dean (education), Oral medicine, Pathology, Case Western Reserve University School of Medicine, Oral and maxillofacial pathology, Sacroiliac joint, University of Siena, ADEA, Western University, American Academy, Association of Christian Universities and Colleges in Asia, Otorhinolaryngology, Diplom, University of Maryland School of Dentistry, Dentistry, New York University, Orofacial pain, Medicine

ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.

Key Points: 
  • ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.
  • The ADEA CDF is a year-long, part-time fellowship aimed at creating a diverse pipeline of future leaders who will assume roles as dental school deans and other senior university leadership positions.
  • The ADEA CDF will increase the number of qualified candidates for deanships and equip them with the skills and experiences to help them succeed.
  • The ADEA CDF Program Director is Dean Emeritus Steven Friedrichsen, D.D.S., of Western University of Health Sciences College of Dental Medicine.

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

Retrieved on: 
Thursday, December 8, 2022
Liver, PDAC, Extracellular matrix, Patient, Neoplasm, Pancreatic cancer, ATX, Diagnosis, Tumor microenvironment, University of Glasgow, Phases of clinical research, Pelareorep, University of Alberta, Safety, Cancer, Drug resistance, Doctor of Philosophy, University of Siena, Drug development, Collagen, University of Verona, Lymphocyte, Immune system, University, Pharmaceutical industry, Medical imaging, Biochemistry

“We are excited to progress clinical development of our autotaxin (ATX) inhibitor IOA-289, the second most advanced product in our pipeline,” said Catherine Pickering, PhD, CEO of iOnctura.

Key Points: 
  • “We are excited to progress clinical development of our autotaxin (ATX) inhibitor IOA-289, the second most advanced product in our pipeline,” said Catherine Pickering, PhD, CEO of iOnctura.
  • Fibrotic cancers, including pancreatic cancer, are characterized by the deposition of thick layers of extracellular matrix containing collagen fibers and pro-tumorigenic factors.
  • Pancreatic cancer (PDAC): Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer accounting for approximately 90% of cases.
  • There are over 50,000 diagnoses of pancreatic cancer each year in the United States and over 65,000 in the EU5.

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease

Retrieved on: 
Monday, November 21, 2022
Doctor of Philosophy, Head, AD, Dementia, MD, University of Siena, Biomarker, Foreign policy, Precision medicine, University, Clinical trial, Blood, University of Cambridge, Research, Dhaneswar Rath Institute of Engineering and Management Studies, Novartis, Government budget balance, CFO, Biology, Patient, Sanofi, GlaxoSmithKline, Diagnosis, CMO, University of Glasgow, Molecular medicine, Chartered accountant, Disease, Genomics, Laboratory, Management, Pharmaceutical industry, Medical device, Medical imaging, Teva, Alzheimer's disease, EU, Engineering, Takeda, Operation, Diadem

MILAN, Nov. 21, 2022 /PRNewswire/ -- Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced key additions to its senior management team. Sam Agus, MD, has been appointed Chief Medical Officer (CMO), James Clarke, PhD, has been named Head, External Affairs and Collaborations, and Peter Bream is Diadem's new Chief Financial Officer (CFO). They join Simona Piccirella, PhD, Vice President of Operations and Development and Chief Executive Officer Paul Kinnon at Diadem.

Key Points: 
  • They join Simona Piccirella, PhD, Vice President of Operations and Developmentand Chief Executive Officer Paul Kinnon at Diadem.
  • Simona has already played a major role in growing Diadem and developing the AlzoSure technology to this stage.
  • Their contributions will be instrumental as we prepare for the commercialization of AlzoSure Predict in the new year."
  • The company is also developing AlzoSure Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies.

Expert.ai and the University of Siena Launch the First Multilingual Crossword Solver Based on Artificial Intelligence

Retrieved on: 
Thursday, June 9, 2022
Knowledge, Information engineering, Human, Language, EDT, Insurance, WebCrow, CTO, Zurich Insurance Group, Associated Press, Decision-making, Crossword, LinkedIn, Artificial intelligence, AI, Software, Publishing, BNP Paribas, Organization, Rabobank, Multimedia, University of Siena, University, NLU, Machine learning, Ambiguity, Gannett, Mathematical sciences, Reading, Department, Heart, AXA, EBSCO, NLP, View, Natural language processing, Humour, Automation, Medical device, Toy, Book, Online shopping, Generali

BOSTON, June 9, 2022 /PRNewswire/ -- Starting today, even machines can solve crossword puzzles thanks to WebCrow 2.0, a software developed by the University of Siena in collaboration with expert.ai (EXAI:IM), a leading company in artificial intelligence (AI) for natural language processing (NLP) and understanding (NLU).

Key Points: 
  • For over a century, crossword puzzles have been an intriguing challenge for humans because of the complexity and nuance of the human language.
  • They must also be able to interpret slang, catch phrases, wordplay and other forms of ambiguity (e.g., a crossword clue: liquid that does not stick, answer: scotch).
  • This allows the software to identify the meaning of words based on definitions and other clues in crossword puzzles.
  • A special LinkedIn NLP stream session, "Solving Crossword Puzzles with WebCrow AI," is scheduled for June 16 at 11:00 am EDT.

Findings in New Book, Neurology in Migrants and Refugees, Presented at the World Congress of Neurology 2021, Raising Awareness on Neurological Issues Facing Migrants and Refugees

Retrieved on: 
Friday, October 8, 2021
Mohammed V University, Twitter, Lists of diseases, Epilepsy, Coronation Dental Specialty Group, Headache, Degenerative disease, Dementia, World government, Neuropsychology, World Federation of Neurology, Palliative care, Attention, Mohammed V of Morocco, WHO, Parkinson's disease, COVID-19, Sustainable development, Medical University of Vienna, Hospital, Migrants and Refugees Section, Diagnosis, Medical school, Health, Center, WCN, SIN, Communication, University, Society, Multiple sclerosis, Sustainable Development Goals, Seizure, Association, Policy, Stroke, Goal, HIV/AIDS, Alzheimer's disease, WFN, Refugee, Language, University of Siena, Congress, Patient, Research, Organization, Movement disorders, Pharmaceutical industry, Personal protective equipment

Neurology in Migrants and Refugees , which is a part of the WHO's Sustainable Development Goals series ,discusses the scientific and epidemiological data of neurological diseases in migrants.

Key Points: 
  • Neurology in Migrants and Refugees , which is a part of the WHO's Sustainable Development Goals series ,discusses the scientific and epidemiological data of neurological diseases in migrants.
  • It provides practical guidelines for the diagnosis and treatment of these diseases and examines the relationship between immigration and neurological diseases in migrants and refugees.
  • It will help focus the issues facing migrants and refugees as they seek medical care, especially for neurological diseases," said Federico.
  • With support from member organizations around the globe, WFN unites the world to allow patients greater access to brain health.

Findings in New Book, Neurology in Migrants and Refugees, Presented at the World Congress of Neurology 2021, Raising Awareness on Neurological Issues Facing Migrants and Refugees

Retrieved on: 
Friday, October 8, 2021
Mohammed V University, Twitter, Lists of diseases, Epilepsy, Coronation Dental Specialty Group, Headache, Degenerative disease, Dementia, World government, Neuropsychology, World Federation of Neurology, Palliative care, Attention, Mohammed V of Morocco, WHO, Parkinson's disease, COVID-19, Sustainable development, Medical University of Vienna, Hospital, Migrants and Refugees Section, Diagnosis, Medical school, Health, Center, WCN, SIN, Communication, University, Society, Multiple sclerosis, Sustainable Development Goals, Seizure, Association, Policy, Stroke, Goal, HIV/AIDS, Alzheimer's disease, WFN, Refugee, Language, University of Siena, Congress, Patient, Research, Organization, Movement disorders, Pharmaceutical industry, Personal protective equipment

Neurology in Migrants and Refugees , which is a part of the WHO's Sustainable Development Goals series ,discusses the scientific and epidemiological data of neurological diseases in migrants.

Key Points: 
  • Neurology in Migrants and Refugees , which is a part of the WHO's Sustainable Development Goals series ,discusses the scientific and epidemiological data of neurological diseases in migrants.
  • It provides practical guidelines for the diagnosis and treatment of these diseases and examines the relationship between immigration and neurological diseases in migrants and refugees.
  • It will help focus the issues facing migrants and refugees as they seek medical care, especially for neurological diseases," said Federico.
  • With support from member organizations around the globe, WFN unites the world to allow patients greater access to brain health.